Product correctly added to cart.

discount label
LOXO-305
View 3D

Biosynth logo

LOXO-305

CAS: 2101700-15-4

Ref. 3D-BL180882

1mg
180.00 €
2mg
270.00 €
5mg
457.00 €
10mg
677.00 €
500µg
120.00 €
Estimated delivery in United States, on Tuesday 21 May 2024

Product Information

Name:
LOXO-305
Synonyms:
  • Pirtobrutinib
Description:

LOXO-305 is a small molecule that inhibits the activity of venetoclax, an inhibitor of BCL2. LOXO-305 has shown efficacy in mouse models for chronic lymphocytic leukemia, which is a type of cancer that originates in white blood cells called lymphocytes. Venetoclax targets the BCL2 protein and inhibits its ability to keep lymphocytes from dying, and thus is used to treat chronic lymphocytic leukemia. Venetoclax also has minimal activity against other types of cancer cells, including those that are resistant to chemotherapy drugs such as doxorubicin or cisplatin. The safety profile for LOXO-305 is also very good with no observed toxicity in mice or monkeys up to doses of 500 mg/kg. This drug has been shown to be potently active in cellular models at concentrations below 10 μM, which may be due to inhibition of the venetoclax target or inhibition of other proteins involved in

Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
479.43 g/mol
Formula:
C22H21F4N5O3
Purity:
Min. 95%
Color/Form:
Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-BL180882 LOXO-305

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".